http://jja-contents.wdc-jp.com/pdf/JJA74/74-1-open/74-1_44-95.pdf

” The Japanese Journal of Antibiotics (peer reviewed, published by Japan Antibiotics Research Association). 52 pages, worth the pot of coffee. Or you can skip to “6. Conclusion”:

The effective concentration of ivermectin against SARS-CoV-2 in an in vitro experiment by Caly et al. is as high as 2 ?M; in clinical practice, it is necessary to administer tens of times the normal dose in order to obtain such a blood concentration. Therefore, there are opinions from the IDSA98) and others that the therapeutic effect of COVID-19 cannot be expected by the administration of the normal dose of ivermectin. However, in actual medical practice, there are many study reports demonstrating that the administration of a normal dose does indeed show a clinical response. As of the 27th of February 2021, the results of 42 clinical studies worldwide have undergone meta-analysis and concluded that ivermectin is effective in the treatment and prevention of COVID-19. In the UK, a consensus-based recommendation by 75 healthcare professionals from 17 countries around the world has been carried out and submitted to the WHO to further encourage the issuance of guidelines for the use of ivermectin in the treatment and prevention of COVID-19. We must consider why such a discrepancy is occurring.

Indeed! Lots of good data on Merck, too. A continuing theme is that many of the small studies are doctor-initiated, and therefore lack the funding that enables a full-blown RCT. The article comments:

Although these doctor-initiated trial results may appear at first glance to be of a poor quality and biased (to eyes familiar with the results of company-oriented clinical trials in the clinical development of traditional anti-infective agents), physicians involved in these trials are enthusiastic about avoiding bias and need to understand the attitude of seriously assessing the efficacy and safety of a study drug. It must be appreciated that they are truly striving to treat and prevent the onset of COVID-19 in patients, for non-profit motives.

Oh, and if I search for “Ivermectin” on the iOS Twitter app, I get generic Covid hits only, and nothing on Ivermectin. Same with #Ivermectin. On the desktop version, I get Ivermectin hits as expected. This behavior seems curious. “